NASDAQ Framework: Revolution Medicines Inc.
Clinical-stage precision oncology company developing targeted therapies 1.
1: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source
Revolution Medicines, Inc., headquartered in Redwood City, California, is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company's innovative RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805, are currently in phase 1 clinical trials, while its RAS companion inhibitors, such as RMC-4630 and RMC-5552, are in phase 2 and phase 1 trials, respectively. Revolution Medicines aims to maximize clinical benefits and circumvent adaptive resistance mechanisms through pioneering combination and monotherapy treatment regimens. Founded in 2014 by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano, and Michael Fischbach, the company is strategically positioned in the oncology market with a strong pipeline and promising clinical data 23.
2: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source3: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA. View Source
UNKNOWN
The provided facts do not specify whether the founders of Revolution Medicines Inc. are still leading the company or are heavily involved in its current operations. The information only mentions that the company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano, and Michael Fischbach in 2014 4.
The provided facts do not specify whether the founders of Revolution Medicines Inc. are still leading the company or are heavily involved in its current operations. The information only mentions that the company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano, and Michael Fischbach in 2014 4.
4: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA. View Source
MEDIUM RISK
Revolution Medicines, Inc. is currently in a clinical-stage with ongoing trials for its targeted therapies, indicating that it is not yet generating revenue from product sales 5. The company reported a loss per share of US$0.70 for Q1 2024, which is a slight improvement from the US$0.72 loss in Q1 2023 6. While the company shows promising clinical data and strategic advances, it still faces financial challenges typical of clinical-stage biotech firms 7. Therefore, the financial situation can be considered medium risk, as the company is not yet profitable and will need to continue managing its resources carefully to cover ongoing expenses and future development costs.
Revolution Medicines, Inc. is currently in a clinical-stage with ongoing trials for its targeted therapies, indicating that it is not yet generating revenue from product sales 5. The company reported a loss per share of US$0.70 for Q1 2024, which is a slight improvement from the US$0.72 loss in Q1 2023 6. While the company shows promising clinical data and strategic advances, it still faces financial challenges typical of clinical-stage biotech firms 7. Therefore, the financial situation can be considered medium risk, as the company is not yet profitable and will need to continue managing its resources carefully to cover ongoing expenses and future development costs.
5: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source6: Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023) View Source7: Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ... View Source
8: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source9: Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data View Source10: Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 View Source
Revolution Medicines Inc. has a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its clinical-stage precision oncology therapies targeting RAS-addicted cancers. The company is progressing with its RAS(ON) inhibitors, including RMC-6236, RMC-6291, and RMC-9805, which are in phase 1 clinical trials, and its RAS companion inhibitors, such as RMC-4630 and RMC-5552, in phase 2 and phase 1 trials, respectively 11. Key strategic initiatives include the planned RASolute 302 study for RMC-6236 set for the second half of 2024 12, and continued development of its innovative RAS(ON) platform, which has shown promising results in preclinical models of refractory KRAS-mutated non-small cell lung cancer 13. The company aims to leverage its strong clinical data and strategic positioning within the oncology market to maximize clinical benefits and address a substantial patient population 1415.
11: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source12: Jonathan Chang has given his Buy rating due to a combination of factors surrounding Revolution Medicines’s promising clinical data and strategic positioning in the oncology market. His confidence is buoyed by the encouraging results from the Phase I study of RMC-6236, particularly in treating pancreatic ductal adenocarcinoma, and the planned RASolute 302 study set for the second half of 2024. Chang’s analysis indicates that the innovative RAS(ON) platform could significantly impact the treatment of RAS-dependent cancers, which represent a substantial patient population. His outlook on Revolution Medicines is further supported by the company’s competitive stance within the multi/pan-RAS targeting therapeutic space. The report also takes into consideration the broader scope of RMC-6236’s potential, including a detailed review of upcoming data for non-small cell lung cancer (NSCLC) and the broader RAS-targeting landscape. Chang has integrated insights from key opinion leaders in thoracic and pancreatic oncology, which likely contributed to his positive stance. Despite the competitive nature of RAS pathway drug development, the uniqueness of Revolution Medicines’s approach and the size of the addressable market for their therapies have led Chang to reiterate an Outperform rating, raising the price target from $53 to $55, indicating a positive long-term outlook for the company’s stock. View Source13: Revolution Medicines Balances 2024 Loss Projection with Promising Cancer Drug Trials Tesla downgraded, Booking Holdings upgraded: Wall Street’s top analyst calls Revolution Medicines initiated with an Overweight at Barclays Revolution reports publication showing anti-tumor activity of RAS(ON) inhibitors Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer View Source14: Jonathan Chang has given his Buy rating due to a combination of factors surrounding Revolution Medicines’s promising clinical data and strategic positioning in the oncology market. His confidence is buoyed by the encouraging results from the Phase I study of RMC-6236, particularly in treating pancreatic ductal adenocarcinoma, and the planned RASolute 302 study set for the second half of 2024. Chang’s analysis indicates that the innovative RAS(ON) platform could significantly impact the treatment of RAS-dependent cancers, which represent a substantial patient population. His outlook on Revolution Medicines is further supported by the company’s competitive stance within the multi/pan-RAS targeting therapeutic space. The report also takes into consideration the broader scope of RMC-6236’s potential, including a detailed review of upcoming data for non-small cell lung cancer (NSCLC) and the broader RAS-targeting landscape. Chang has integrated insights from key opinion leaders in thoracic and pancreatic oncology, which likely contributed to his positive stance. Despite the competitive nature of RAS pathway drug development, the uniqueness of Revolution Medicines’s approach and the size of the addressable market for their therapies have led Chang to reiterate an Outperform rating, raising the price target from $53 to $55, indicating a positive long-term outlook for the company’s stock. View Source15: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. View Source